Clinical risk factors in patients with interstitial lung disease associated with anti-MDA5 autoantibodies

被引:0
|
作者
Ramos-Martinez, Espiridion [1 ]
Rodriguez-Vega, Eric A. [2 ]
Rivera-Matias, Pedro A. [2 ,3 ]
Falfan-Valencia, Ramces [4 ]
Perez-Rubio, Gloria [4 ]
Mejia, Mayra [2 ]
Gonzalez-Perez, Montserrat I. [2 ]
Buendia-Roldan, Ivette [5 ]
Mateos-Toledo, Heidegger N. [2 ]
Serrano, Jorge Rojas [2 ,6 ]
机构
[1] Univ Nacl Autonoma Mexico, Fac Med, Expt Med Res Unit, Mexico City, Mexico
[2] Inst Nacl Enfermedades Resp Ismael Cosio Villegas, Interstitial Lung Dis & Rheumatol Unit, Calzada Tlalpan 4502,Secc 16, Mexico City 14080, Mexico
[3] Becario Direcc Gen Calidad & Educ Salud, Mexico City, Mexico
[4] Inst Nacl Enfermedades Resp Ismael Cosio Villegas, HLA Lab, Calzada Tlalpan 4502,Secc 16, Mexico City 14080, Mexico
[5] Inst Nacl Enfermedades Resp Ismael Cosio Villegas, Res Direct, Calzada Tlalpan 4502,Secc 16, Mexico City 14080, Mexico
[6] Univ Nacl Autonoma Mexico, Fac Med, Programa Maestria & Doctorado Ciencias Med, Mexico City, Mexico
来源
MEDICINA CLINICA | 2023年 / 161卷 / 12期
关键词
Interstitial lung disease; Anti-MDA5; Nonspecific interstitial pneumonia; Inflammatory myopathies; DERMATOMYOSITIS PATIENTS; ANTIBODY; MDA5; RECOGNITION; EXPRESSION;
D O I
10.1016/j.medcli.2023.07.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: The anti-MDA5-associated autoimmune disease represents a poorly understood entity. The study's objectives were to describe a cohort of interstitial lung disease (ILD) patients who were positive for anti-MDA5 autoantibody and identify clinical risk factors associated with survival. Methods: This single-center cohort study included ILD patients positive for anti-MDA5 autoantibody. Baseline clinical features were registered, and survival analysis was performed to identify risk factors associated with worse survival. Results: Fifty-three ILD-MDA5 positive patients were included; twelve died during follow-up due to rapidly progressive interstitial lung disease (RP-ILD). Dermatological signs of anti-MDA5 (Gottron papules, Gottron sign, palmar papules, V-neck sign, facial dermatomyositis rashes, and skin ulcers) were strongly associated with death secondary to RP-ILD (HR: 3.7, 95% CI: 1.02-13.35). Patients with dermatological signs were younger, had higher anti-MDA5 autoantibodies titers, more frequent inflammatory patterns in HRCT evaluation, and less fibrosis extent in HRCT. Conclusion: Dermatological manifestation in ILD patients to anti-MDA5 autoantibodies are associated with RP-ILD and short-term fatal outcomes. Dermatological signs may identify a subgroup of ILD-positive to anti-MDA5 patients with a high risk of RP-ILD. (c) 2023 Elsevier Espan similar to a, S.L.U. All rights reserved.
引用
收藏
页码:515 / 522
页数:8
相关论文
共 50 条
  • [31] Mortality risk in patients with anti-MDA5 dermatomyositis is related to rapidly progressive interstitial lung disease and anti-Ro52 antibody
    Wang, Huyan
    Chen, Xin
    Du, Yan
    Wang, Lihua
    Wang, Qiyuan
    Wu, Huaxiang
    Liu, Lei
    Xue, Jing
    ARTHRITIS RESEARCH & THERAPY, 2023, 25 (01)
  • [32] MDA5 expression is associated with TGF-β-induced fibrosis: potential mechanism of interstitial lung disease in anti-MDA5 dermatomyositis
    Shen, Ning
    Zhou, Xiaopeng
    Jin, Xuexiao
    Lu, Ci
    Hu, Xiuhua
    Zhang, Yichi
    Jiang, Yu
    Xu, Qin
    Xu, Xiayan
    Liu, Minghao
    Lu, Linrong
    Han, Yongmei
    RHEUMATOLOGY, 2022, 62 (01) : 373 - 383
  • [33] LUNG TRANSPLANTATION IN PATIENTS WITH INTERSTITIAL LUNG DISEASE ASSOCIATED WITH ANTISYNTHETASE AND ANTI-MDA5 SYNDROMES. EXPERIENCE FROM A REFERENCE SPANISH HOSPITAL
    Trallero-Araguas, E.
    Berastegui, C.
    Lopez-Corbeto, M.
    Bello, I.
    Roman, A.
    Selva-O'Callaghan, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 900 - 900
  • [34] Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease
    Fujisawa, Tomoyuki
    Hozumi, Hironao
    Yasui, Hideki
    Suzuki, Yuzo
    Karayama, Masato
    Furuhashi, Kazuki
    Enomoto, Noriyuki
    Nakamura, Yutaro
    Inui, Naoki
    Suda, Takafumi
    JOURNAL OF RHEUMATOLOGY, 2019, 46 (08) : 935 - 942
  • [35] CLINICAL FEATURES IN RECURRENCE OF ANTI-MDA5 AUTOANTIBODIES POSITIVE DERMATOMYOSITIS
    Yamaguchi, Koichi
    Yamaguchi, Aya
    Kashiwagi, Chiharu
    Masubuchi, Hiroaki
    Hara, Kenichiro
    Koga, Yasuhiko
    Sunaga, Noriaki
    Maeno, Toshiaki
    RESPIROLOGY, 2019, 24 : 81 - 82
  • [36] Efficiency of tofacitinib in refractory interstitial lung disease among anti-MDA5 positive juvenile dermatomyositis patients
    Xue, Yuan
    Zhang, Junmei
    Deng, Jianghong
    Kuang, Weiying
    Wang, Jiang
    Tan, Xiaohua
    Li, Chao
    Li, Shipeng
    Li, Caifeng
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (11) : 1499 - 1501
  • [37] Evaluation of clinical prognostic factors for interstitial pneumonia in anti-MDA5 antibody-positive dermatomyositis patients
    Fujiki, Youhei
    Kotani, Takuya
    Isoda, Kentaro
    Ishida, Takaaki
    Shoda, Takeshi
    Yoshida, Shuzo
    Takeuchi, Tohru
    Makino, Shigeki
    MODERN RHEUMATOLOGY, 2018, 28 (01) : 133 - 140
  • [38] Rapidly progressive interstitial lung disease complicated by pulmonary interstitial emphysema in anti-MDA5 amyotrophic dermatomyositis
    Kenyon, Sarrinder
    Careless, David
    Navaratnam, Vidya
    Reddy, Taryn
    THORAX, 2023, : 946 - 947
  • [39] Efficacy and safety of combined immunosuppressive therapies in anti-MDA5 dermatomyositis with interstitial lung disease
    Nguyen, Chilan
    Ennis, Samantha
    Nguyen, John Trinh
    Ta, Brenda
    Tho Phu Pham
    Parsons, Stephen
    RESPIROLOGY, 2023, 28 : 411 - 412
  • [40] HRCT in accessing of interstitial lung disease in dermatomyositis with positive expression of anti-MDA5 autoantibody
    Diao, L.
    Chen, M.
    Zhu, X.
    Xue, K.
    Cao, H.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (05) : S1 - S1